

PARTICULARS TO APPEAR ON THE OUTER PACKAGE
CARDBOARD BOX
50 doses, 100 doses

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Colombovac PMV suspension for injection

2. STATEMENT OF ACTIVE SUBSTANCES

Each 0.2 ml dose contains:

Newcastle disease virus, inactivated, strain La Sota contains at least 19.9 AU.

3. PACKAGE SIZE

50 doses (10 ml)

100 doses (20 ml)

4. TARGET SPECIES

Pigeons.

5. INDICATIONS

6. ROUTES OF ADMINISTRATION

Subcutaneous use.

7. WITHDRAWAL PERIODS

Withdrawal period: Zero days.

8. EXPIRY DATE

Exp. {mm/yyyy}

Once opened use immediately.

9. SPECIAL STORAGE PRECAUTIONS

Store and transport refrigerated.

Do not freeze.

Protect from light.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

Zoetis UK Limited

14. MARKETING AUTHORISATION NUMBERS

Vm 42058/5229

15. BATCH NUMBER

Lot {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING
UNITS
VIAL LABEL
50 doses, 100 doses

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Colombovac PMV

2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

Each 0.2 ml dose contains:

Newcastle disease virus, inactivated, strain La Sota contains at least 19.9 AU.

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

Once broached use immediately.

PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

Colombovac PMV suspension for injection

2. Composition

Each 0.2 ml dose contains:

Active substance:

Newcastle disease virus, inactivated, strain La Sota at least 19.9AU*

*AU: Antigen Unit

Adjuvant:

Carbomer 934 P 1 mg

Excipients:

Thiomersal 20 µg

Off-white liquid.

3. Target species

Pigeons.

4. Indications for use

For active immunisation of pigeons to reduce mortality and clinical signs due to paramyxovirus serotype 1 infection.

Onset of immunity: 4 weeks.

Duration of immunity: 1 year.

5. Contraindications

Do not vaccinate during the last 2 weeks prior to mating.

6. Special warnings

Special warnings:

Vaccinate healthy animals only.

Special precautions for safe use in the target species:

Not for intramuscular injection: Intramuscular injection causes severe adverse reactions. Maternally derived antibodies (MDA) can interfere with the development of active immunity. Where it is likely that recent field infection or vaccination of the parent flock has stimulated a high antibody titre and consequently a high level of MDA, the timing of the vaccination programme should be planned accordingly.

In cases of hypersensitivity reactions treat immediately with glucocorticoid intravenously or adrenaline intramuscularly.

The incubation period for pigeon paramyxovirus may be a few days to several weeks. However, after infection with the wild virus, pigeons excrete the virus from the eye and in the droppings within 3-4 days. This means that infected birds can be a danger to others some days before their own symptoms appear. Excretion of wild virus from the infected bird continues for up to 6 weeks. This information is important since, in addition to direct bird to bird contact at competition and shows, the disease can be spread by indirect means such as hands, overalls, caps, boots and contaminated objects such as baskets and trucks.

An owner should forbid visits to the loft by anyone in contact with unvaccinated pigeons and new birds (either purchased or lent for mating) should not be brought in unless vaccinated at least 14 days previously.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

Laying birds:

Do not use in birds in lay or within 4 weeks before the start of the laying period.

Fertility:

Vaccination is safe in breeding birds provided they are vaccinated before the start of breeding.

Interaction with other medicinal products and other forms of interaction:

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case-by-case basis.

Overdose:

An overdose may result in an increase of the degree of local reactions.

Major incompatibilities:

Do not mix with any other veterinary medicinal product.

7. Adverse events

Pigeons:

Very common (>1 animal / 10 animals treated):	Injection site swelling ¹
---	--------------------------------------

¹ Up to 1 cm in diameter, which may last up to 4 weeks or more. They tend to disappear without treatment. In cases of adverse reactions not disappearing spontaneously the veterinary surgeon should be contacted.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package

leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system at:

E-mail: adverse.events@vmd.gov.uk

Website: <https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine>

8. Dosage for each species, routes and method of administration

Dose: One dose (0.2 ml) per pigeon.

The vaccine has to be administered by subcutaneous injection dorsally in the neck region (in the direction of the back).

9. Advice on correct administration

Administration: The vial has to be swirled several times before use.

Primary vaccination:

Racing Pigeons

All birds in the loft should be given one vaccination annually not less than 14 days before the beginning of the racing season.

Young birds may be vaccinated with the veterinary medicinal product from 3 weeks of age when a single injection will provide immunity for 1 year.

Following vaccination avoid contact with birds from other lofts for at least 14 days.

Show Pigeons

All birds on the premises should be given one vaccination annually not less than 14 days before the beginning of the show season.

Young birds may be vaccinated with the veterinary medicinal product from 3 weeks of age when a single injection will provide immunity for 1 year.

Following vaccination avoid contact with birds from other sources for at least 14 days.

Booster vaccination:

Racing Pigeons

All adult birds in the loft should be given a single booster vaccination annually.

Where the annual booster vaccination may interfere with the training or racing programme, it may be brought forward prior to the commencement of each racing season.

Show Pigeons

All adult birds on the premises should be given a single booster vaccination annually.

10. Withdrawal periods

Zero days.

11. Special storage precautions

Keep out of the sight and reach of children.
Store and transport refrigerated (2 °C – 8 °C).
Do not freeze.
Protect from light.

Do not use this veterinary medicinal product after the expiry date which is stated on the label. The expiry date refers to the last day of that month.

Shelf life after first opening the immediate packaging: use immediately.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater or household waste.
Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.
Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. MARKETING AUTHORISATION NUMBERS AND PACK SIZES

Vm 42058/5229

Nature: 20 ml, Type hydrolytic I glass vial (Ph. Eur.).
Closure: Butyl rubber stopper (Ph. Eur.), sealed by 20 mm aluminium “tear-off” cap.
Cardboard box containing: 1 x 50 doses (10 ml) or 1 x 100 doses (20 ml).

Not all pack sizes may be marketed.

15. PID LINK (Do not print heading)

[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]

Find more product information by searching for the ‘Product Information Database’ on www.gov.uk.

16. Contact details

Marketing authorisation holder and contact details to report suspected adverse reactions:

Zoetis UK Limited
1st Floor, Birchwood Building
Springfield Drive
Leatherhead
Surrey
KT22 7LP
Phone: +44 (0) 345 300 8034

Manufacturer responsible for batch release:

Zoetis Manufacturing & Research Spain S.L.
Carretera De Camprodon S/n
La Vall De Bianya
17813 Girona
Spain

17. Other information

POM-VPS

Gavin Hall
Approved: 13 March 2026